You are here: Home > Products >

EndoFectin™ Transfection Reagents

A versatile & efficient suite of robust transfection reagents

EndoFectin Max

Introducing EndoFectin™ Max

EndoFectin™ Max is a new lipid-based transfection reagent. This versatile transfection reagent has been tested and optimized for highly efficient transfection of a large collection of commonly used cell lines as well as many difficult-to-transfect cell lines.      

 

Advantages

  • Equal to or greater transfection efficiency compared with Lipofectamine® 3000 in plasmid transfection (Figure 1).
  • Superior transfection efficiency for a broad range of cell lines compared with Lipofectamine® 2000 (Figures 2 and 3).
  • Equal to or greater transfection efficiency compared with Lipofectamine® 2000 in siRNA transfection (Figure 4).
  • Low cytotoxicity (Figure 5).
  • Does not require removal of serum or culture medium, or removal of medium after transfection.
  • For overexpression, knockdown, knockout, as well as high-throughput applications

 

Buy Cat.No. Product name Price Protocol MSDS
EF013 EndoFectin™ Max transfection reagent (1 mL) $295 Download Download
EF014 EndoFectin™ Max transfection reagent (3 mL) $589

 

 

 

Experiment 1: Comparison of EndoFectin™ Max and Lipofectamine® 3000 in plasmid transfection

A B
       
C D
       
E F
 

Figure 1. Transfection of 6 commonly-used cell lines using either EndoFectin™ Max, Lipofectamine® 2000 (LP2000) or Lipofectamine® 3000 (LP3000). Cell lines were transfected with a firefly luciferase-expressing plasmid. Transfection efficiencies were assessed by luciferase activity (RLU). Note: for HEK293 (A), HeLa (C), A549 (D), H1299 (E), and 1321N1 (F), 0.15 uL/well of Lipofectamine® 3000 was used rather than 0.2 uL/well. Lipofectamine® is a trademark of Invitrogen.

 

Experiment 2: Comparison of EndoFectin™ Max and Lipofectamine® 2000 in plasmid transfection

A
 
B
 
C
 
Figure 2. Transfection of 17 commonly-used cell lines using either EndoFectin™ Max or Lipofectamine® 2000 (LP-2000). Cell lines with low transfection efficiency (A), medium transfection efficiency (B), and high transfection efficiency (C) were transfected with a firefly luciferase-expressing plasmid. Transfection efficiencies were assessed by luciferase activity (RLU). Lipofectamine® is a trademark of Invitrogen.

 

 
Figure 3. Assessment of EndoFectin™ Max transfection efficiencies using GFP visualization. 16 commonly-used cell lines were transfected with a GFP-expressing plasmid using either EndoFectin™ Max or Lipofectamine® 2000 (LP-2000). Cells were visualized 48 hours post-transfection under phase contrast or fluorescence microscopy (GFP filter). Lipofectamine® is a trademark of Invitrogen.
 

 

Experiment 3: Comparison of EndoFectin™ Max and Lipofectamine® 2000 in siRNA transfection

A B
 
Figure 4. Comaprison of transfection of siRNA between EndoFectin™ Max and Lipofectamine® 2000, Cell lines H1299 (A) and HEK293 (B) were transfected with either a firefly luciferase-expressing plasmid (blue bars), or co-tranfected with a firefly luciferase-expressing plasmid and an anti-luciferase siRNA (red bars). Transfection efficiencies were assessed by luciferase activity (RLU). Lipofectamine® is a trademark of Invitrogen.

 

Experiment 4: Comparison of EndoFectin™ Max and Lipofectamine® 2000 for cytotoxicity

 
Figure 5. Comparison of cytotoxicity between EndoFectin™ Max and Lipofectamine® 2000. Lipofectamine® is a trademark of Invitrogen.

 

Related Products